DEVELOPING A MECHANISTIC UNDERSTANDING TO LINK ALK MUTATIONS TO PROGNOSIS AND THERAPEUTIC INHIBITOR CHOICE IN NEUROBLASTOMA PATIENTS

The Children'S Hospital Of Philadelphia, Philadelphia PA

Investigators